MDMarine Delecourt-Billet

Marine Delecourt-Billet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Marine Delecourt-Billet has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Alessandro Mauriello

    Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy

    1 shared publication
  • Antoine Pinton

    Institut Necker Enfants-Malades, INSERM U1151, Paris, France

    1 shared publication
  • Arthur Taveras

    X4 Pharmaceuticals, Boston, Massachusetts

    1 shared publication
  • Audrey Anna Bolyard

    Department of Medicine, University of Washington, Seattle, Washington, DC

    1 shared publication
  • Aurelie Cabannes-Hamy

    Centre Hospitalier de Versailles, Le Chesnay, France

    1 shared publication
  • Bérénice Schell

    Université Paris Cité, Institut de Recherche Saint-Louis, INSERM U1160 Paris, France; OPALE Carnot Institute, The Organization for Partnerships in Leukemia, Hôpital Saint-Louis, Paris, France

    1 shared publication

Latest Publications

  • Open Access

    Clinicopathologic Features and the Spectrum of Myelokathexis in Warts, Hypogammaglobulinemia, Infections, Myelokathexis Syndrome

    by Jingwei Li, Marine Delecourt-Billet, Odile Fenneteau, Jadee L. Neff, Lilian Roland, Bérénice Schell, Vanessa Gourhand, Marion Espeli, Karl Balabanian, Sarah Taplin, et al.


  • Open Access

    IL7-receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK-inhibition

    by Lucien Courtois, Aurelie Cabannes-Hamy, Rathana Kim, Marine Delecourt, Antoine Pinton, Guillaume Charbonnier, Mélanie Féroul, Charlotte Smith, Giulia Tueur, Cecile Pivert, et al.

    T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal prognosis related to refractory/relapsing diseases, raising the need for new targeted-therapies. Activating mutations of the IL7-receptor pathway genes (IL7Rp) play a proven leukemia-supportive role in T-ALL. JAK-inhibitors such as ruxolitinib have recently demonstrated preclinical efficacy. However, prediction markers for sensitivity to JAK-inhibitors are still lacking. Herein, we show that IL7R (CD127) expression is more frequent (~70%) than IL7Rp-mutations in T-ALL (~30%). We compared the so-called non-expressers (no IL7R-expression/IL7Rp-mutation), expressers (IL7R-expression without IL7Rp-mutation) and mutants (IL7Rp-mutations). Integrative multi-omics analysis outlined IL7R-deregulation in virtually all T-ALL subtypes, at the epigenetic-level in non-expressers, genetic-level in mutants, and post-transcriptional level in expressers. Ex-vivo data using primary-derived xenografts support that IL7Rp is functional whenever the IL7R is expressed, regardless of the IL7Rp mutational status. Consequently, ruxolitinib impaired T-ALL survival in both expressers and mutants. Interestingly, we show that expressers displayed ectopic IL7R-expression and IL7Rp-addiction conferring a deeper sensitivity to ruxolitinib. Conversely, mutants were more sensitive to venetoclax than expressers. Overall, combination of ruxolitinib and venetoclax resulted in synergistic effects in both groups. We illustrate the clinical relevance of this association by reporting achievement of complete remission in two patients with refractory/relapsed-T-ALL. This provides proof of concept for translation of this strategy into clinics as bridge to transplant. Altogether, IL7R-expression can be used as a biomarker for sensitivity to JAK-inhibition, thereby expanding the fraction of T-ALL patients eligible to ruxolitinib up to nearly ~70% of T-ALL.